Clinical Trials Directory

Trials / Unknown

UnknownNCT00751517

Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides

Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial.

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
—
Sponsor
University of Parma · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The Systemic Necrotizing Vasculitides (SNV) encompass a group of rare diseases which include Wegener's Granulomatosis (WG), Churg-Strauss Syndrome (CSS), Microscopic polyangiitis (MPA)and Polyarteritis nodosa (PAN). Common histological findings are inflammation with fibrinoid necrosis of the small vessels and sporadic or absent immune-deposits. The gold standard therapy for SNV is currently represented by the association of Cyclophosphamide and Prednisone. The limits of this approach are the high frequency of recurrent disease and an increased incidence of malignancy and infections. The aim of the present study is to compare the efficacy of Methotrexate vs Cyclophosphamide for Remission Maintenance in SNV.

Conditions

Interventions

TypeNameDescription
DRUGMethotrexate
DRUGCyclophosphamide

Timeline

First posted
2008-09-12
Last updated
2008-09-12

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT00751517. Inclusion in this directory is not an endorsement.